Codexis Reports Second Quarter 2026 Financial Results

August 12, 2026 - 01:41

Codexis, Inc. has reported financial results for the second quarter of 2026, posting revenue of $14.9 million. The company also reiterated its full-year financial guidance, signaling confidence in its operational trajectory despite a mixed quarterly performance.

During the quarter, Codexis highlighted significant progress in RNA therapeutic manufacturing. At the recent TIDES US conference, the company presented new data demonstrating that its ECO Synthesis Manufacturing Platform achieves enzyme-driven stereoisomer control of small interfering RNA (siRNA). This advance is seen as a critical step in improving the purity and scalability of next-generation oligonucleotide drugs, a segment where manufacturing complexity has historically been a bottleneck.

In addition to its scientific milestones, Codexis completed an equity capital raise, securing approximately $25 million in net proceeds. The infusion is expected to support ongoing research and development efforts as well as general corporate purposes.

The company's leadership emphasized that the second quarter results align with internal expectations, and the reaffirmed guidance reflects a steady path toward its stated financial goals for the year. Management noted that while market conditions remain dynamic, the combination of new technological capabilities and a strengthened balance sheet positions the firm well for sustained growth.

Codexis continues to focus on its core strategy of delivering enzymatic solutions across pharmaceutical and industrial applications, with a particular emphasis on expanding its footprint in the emerging RNA therapeutics space.